The utility of microdosing over the past 5 years
Expert Opinion on Drug Metabolism & Toxicology November 28, 2008 Graham Lappin, R Colin Garner 89 citations
BACKGROUND: Microdosing studies (human Phase 0) are used to select drug candidates for Phase I clinical trials on the basis of their pharmacokinetic properties, using subpharmacologic doses (maximum 100 microg). There are questions as to whether pharmacokinetic data obtained at these low doses will predict those at the clinically relevant dose. OBJECTIVE: To review the current literature on...